Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus TESTRED.
ANDROID 5 vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category C
Category C
Androgen
Androgen